(495) 988-47-94
(495) 988-47-95
(49243) 7-31-04
info@ibcgenerium.ru
Alethia Biotherapeutics Submits a Clinical Trial Application (CTA) for a Phase I Study with AB-16B5, an Inhibitor of EMT in Patients with Advanced Cancers
XL-protein and GENERIUM sign broad therapeutic license
Archive by year:
2 July 2013
Russian
